Biotechs today are flush with cash – but low on valuation
The biotech markets have softened. What's the state of the forthcoming biotech IPO? Atlas Venture's Bruce Booth weighs in.
9 great nominees for the FDA Patient Engagement Advisory Committee
The FDA has yet to pick the nine members who will make up its new Patient Engagement Advisory Committee. Who should take those spots?
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
RaNA Therapeutics CEO reflects: There’s no sugarcoating the process of raising biotech venture capital. It’s hard.
There are plus and minus points when you compare public and private life sciences companies. Raising biotech venture capital is a constant grind. "I joined RaNA in November and learned very quickly that as a private company CEO, I was always going to be in capital-raising mode," RaNA Therapeutics CEO Ron Renaud says.
With new $280M fund, Atlas Venture cuts the IT and “right-sizes” to biotech
Atlas Venture just closed its tenth fund at $280 million – marking its switch over to a biotech-only firm, the firm’s Bruce Booth blogged today. “At our core, we’re biotech therapeutics startup folks, and that’s where we’re going to focus,” he wrote. Conversely the company’s last fund, at $265 million in 2013, was split between […]
A lesson on biotech CEO dynamics using… thermodynamics!
Venture capitalist Bruce Booth likened CEO dynamics to thermodynamics in a blog that uses scientific parlance to describe leadership challenges to the nerdy biotech set. The metaphors are pretty out of control. Explosive? For instance, as in thermodynamic reactions, Booth asserts there are two kinds of CEOs – exothermic (energy releasing) and endothermic (energy absorbing). The exothermic CEO is […]
Biotech and the World Cup: Some uncanny similarities
There are some distinct parallels between the World Cup and the biotech biz, or so says Bruce Booth of Atlas Venture in an entertaining but spot-on recent blog post. As we enter the frenzied final days of the international soccer tournament, we’d be well-served to hang onto some lessons learned from the sport (before America forgets about […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Biotech investor shares lessons learned from bad investment in healthcare
One of the things that makes successful serial entrepreneurs so inspiring is that even when they fail, they evaluate where they went wrong, begin again and learn from their mistakes. Frequently they share that knowledge with others. Anyone looking for confirmation of that should take a look at the wealth of insights in CB Insights […]